Fecal Transplants Raise Chronic Constipation Relief Rates by 21%, Meta-Analysis of 1,710 Patients Finds

If fiber and laxatives haven't fixed your gut, a growing body of research suggests the problem might live in your microbiome, not just your colon. A new meta-analysis pooling 32 studies and 1,710 patients found that fecal microbiota transplantation (FMT), transferring stool derived gut bacteria from a healthy donor into a patient's digestive tract, meaningfully raised the odds of relief from chronic constipation. The catch: even the researchers who ran the numbers rate the overall certainty of that evidence as very low.

Key takeaways

• Pooling 32 studies (1,710 patients total), FMT raised the rate of clinical improvement in chronic constipation by an adjusted 21% (RR = 1.21) once the researchers corrected for likely publication bias, down from an uncorrected estimate of 36%.
• About half of patients in the smaller single arm studies, 51.7%, went into full remission after FMT.
• FMT was well tolerated through 24 weeks of follow up, with only mild, self resolving side effects like bloating and gas.
• The study's own authors rate the overall certainty of the evidence as very low, citing high risk of bias in every included randomized trial.

Fecal Microbiota Transplantation's Effect on Chronic Constipation Response Rates

Fecal microbiota transplantation raised the rate of clinical improvement in chronic constipation patients by an adjusted 21% relative to standard care, according to a meta-analysis published in Frontiers in Microbiology that pooled data from 32 studies covering 1,710 patients. The analysis combined 12 randomized controlled trials (RCTs, n = 1,040), 16 single arm studies (n = 403), and 4 cohort studies (n = 422). The raw, uncorrected pooled effect was a relative risk (RR, how much more likely a treated patient is to improve compared with a control) of 1.36, meaning a 36% higher response rate. But a statistical test for publication bias came back positive, so the researchers applied a standard correction that pulled the adjusted figure down to RR = 1.21 (95% confidence interval 1.10 to 1.33), still a statistically significant benefit. Patients also saw their Wexner score, a standard 0 to 30 clinical scale for constipation severity where lower is better, improve by an average of 2.08 points more than controls.

Why Chronic Constipation and IBS-C Patients Should Care About This

Chronic constipation affects roughly 12% to 17% of adults worldwide, making it one of the most common yet stubbornly hard to treat gastrointestinal complaints, and conventional treatments like polyethylene glycol or lactulose have limited efficacy for refractory cases, with high recurrence and side effects. For readers with chronic idiopathic constipation, slow transit constipation, or IBS-C who haven't gotten full relief from standard laxatives, this is exactly the population the meta-analysis' patients most resemble: people whose conventional treatment options had already fallen short.

Inside the Study's Three Part Meta-Analysis Framework

The researchers combined three separate statistical approaches, a random effects meta-analysis of the randomized trials, a proportional meta-analysis of the single arm studies, and a paired pre-post sensitivity analysis, to pull usable evidence out of a literature that is short on large head to head trials. They searched four databases (CENTRAL, PubMed, Embase, and CNKI) and screened over 1,000 candidate studies down to the 32 included. Of the 16 single arm studies, 8 (n = 249) reported clean remission and improvement data: a pooled remission rate of 51.7% (95% CI 40.3% to 62.9%) and an improvement rate of 67.0% (95% CI 54.3% to 77.6%). FMT was delivered via gastroscopy, nasoenteric tube, oral capsule, or colonoscopy, and the route made no statistically significant difference to effectiveness (gastroscopy RR = 1.42, nasoenteric tube RR = 1.38, oral capsules RR = 1.25, interaction p = 0.87). A single course of FMT also performed comparably to multiple repeated courses (pooled RR = 1.35, 95% CI 1.15 to 1.59, p = 0.46).

What This Means If You're Managing Constipation or IBS-C

Don't expect a fecal transplant to be on the menu at your next gastroenterology visit for constipation specifically. The only FDA-approved FMT-based products, Rebyota and Vowst, are cleared solely to prevent recurrent Clostridioides difficile infection after antibiotic treatment, not for constipation. The plausible mechanism here fits a broader, better documented pattern in gut microbiome research on the bacteria-gut motility connection: people with constipation tend to have fewer butyrate producing bacteria such as Faecalibacterium prausnitzii and more methane producing bacteria such as Methanobrevibacter smithii, a shift associated with slowed colonic transit and altered gut sensitivity. Interestingly, blood tests in the trials also showed FMT recipients had significant increases in substance P (a signaling molecule involved in gut motility) and significant drops in anxiety and depression scores, hinting at a gut-brain axis connection, though those were secondary, exploratory measurements, not the study's main outcome. If you're managing chronic constipation, this is worth a conversation with a gastroenterologist about whether a clinical trial is an option, not a DIY procedure to pursue on your own.

The Evidence Gaps That Keep This From Being a Slam Dunk

Every randomized trial folded into this analysis was rated at high risk of bias, and the study's own authors score the overall certainty of evidence for every primary outcome as "very low" using the GRADE framework, the same rigorous standard used across evidence based medicine to grade confidence in a result. The Harbord test for publication bias came back positive (p = 0.003), which is why the headline number was corrected downward from RR 1.36 to RR 1.21 in the first place. Two other outcomes, a stool form scale (BSFS) and a quality of life measure (PAC-QOL), showed such extreme inconsistency across studies (statistical heterogeneity above 96%) that the authors flag those specific results as unstable. On safety, no serious adverse events turned up during follow up periods of up to 24 weeks, but more than half the included trials didn't report a follow up duration at all, so nothing is known about risks beyond six months.

What Comes Next for FMT and Constipation Research

The authors are calling for larger, sham-controlled randomized trials before FMT can be considered a validated treatment for chronic constipation, and this systematic review itself was pre-registered in the PROSPERO clinical evidence registry (CRD420261394673), a step meant to reduce the risk of the analysis being shaped after the fact by its own results. Encouragingly, the paper notes that its 51.7% remission figure lines up closely with a smaller, independent prior meta-analysis, a sign the core effect may be reproducible even if the certainty grade stays low for now.

Common Questions

Is fecal microbiota transplantation approved to treat constipation? No. The two FDA-approved FMT-based products are cleared only to prevent recurrent C. difficile infection after antibiotics; using FMT for constipation remains experimental and is not an approved treatment.

What side effects did patients report? Mild issues, bloating, diarrhea, nausea, and increased gas, all of which resolved on their own within the tracked follow-up window of up to 24 weeks; no serious adverse events were reported.

Does the delivery method matter? Not significantly in this analysis. Gastroscopy, nasoenteric tube, oral capsules, and colonoscopy all produced comparable improvement rates.

Why is the "corrected" number lower than the raw one? Statistical tests suggested some unfavorable studies may be missing from the published literature, so the researchers applied a standard trim-and-fill correction, which brought the estimated benefit down from a relative risk of 1.36 to a more conservative 1.21.

References

1. Zhihong Huang, Zhenwei Dai, Qihong Liu (2026). Efficacy and safety of fecal microbiota transplantation for chronic constipation: a systematic review and meta-analysis integrating pre-post and single-arm evidence. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2026.1900353
2. Ji Won Youn, Hajung Joo, Soeun Kim, et al. (2026). Global Prevalence of Functional Constipation Across All Age Groups According to Rome II–IV Criteria, 1999–2025: A Systematic Review and Meta-Analysis. Clinical and Translational Gastroenterology. https://doi.org/10.14309/ctg.0000000000001029
3. Shi Hong Liu, Xue Fang Yang, Lei Liang, et al. (2025). Regulatory mechanisms of the gut microbiota-short chain fatty acids signaling axis in slow transit constipation and progress in multi-target interventions. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2025.1689597